Pharvaris N.V. (PHVS) shares have risen 11.2% in the last four weeks, closing at $35.07. Wall Street analysts forecast a mean price target of $47.75, indicating a potential upside of 36.2%, based on 12 short-term estimates with a standard deviation of $11.01. The lowest estimate is $33.00, suggesting a 5.9% decline, while the highest forecast anticipates a surge to $74.00, representing a 111% increase.
Analysts are optimistic about Pharvaris’ earnings prospects, as indicated by a 0.5% increase in the Zacks Consensus Estimate over the past 30 days, with no negative revisions reported. Pharvaris is currently ranked #2 (Buy) by Zacks, placing it in the top 20% of over 4,000 stocks based on earnings estimates. This ranking serves as a stronger indication of the stock’s potential upside in the near term.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
